BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37995023)

  • 1. Current practice in intermediate risk differentiated thyroid cancer - a review.
    do Prado Padovani R; Duarte FB; Nascimento C
    Rev Endocr Metab Disord; 2024 Feb; 25(1):95-108. PubMed ID: 37995023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer.
    Juweid ME; Tulchinsky M; Mismar A; Momani M; Zayed AA; Al Hawari H; Albsoul N; Mottaghy FM
    Int J Cancer; 2020 Nov; 147(9):2345-2354. PubMed ID: 32319676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer.
    Abe K; Ishizaki U; Ono T; Horiuchi K; Kanaya K; Sakai S; Okamoto T
    Ann Nucl Med; 2020 Feb; 34(2):144-151. PubMed ID: 31834567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.
    Rivkees SA; Mazzaferri EL; Verburg FA; Reiners C; Luster M; Breuer CK; Dinauer CA; Udelsman R
    Endocr Rev; 2011 Dec; 32(6):798-826. PubMed ID: 21880704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
    Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
    Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer.
    Handkiewicz-Junak D; Wloch J; Roskosz J; Krajewska J; Kropinska A; Pomorski L; Kukulska A; Prokurat A; Wygoda Z; Jarzab B
    J Nucl Med; 2007 Jun; 48(6):879-88. PubMed ID: 17536106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative remnant
    Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
    Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated thyroid carcinoma: a population-based study.
    Zhang H; Cai Y; Zheng L; Zhang Z; Jiang N
    Hell J Nucl Med; 2017; 20(1):3-10. PubMed ID: 28315902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variations in Radioiodine Therapy in Europe: Decision-Making after Total Thyroidectomy.
    Forrer F; Fischer GF; Maas O; Giovanella L; Hoffmann M; Iakovou I; Luster M; Mihailovic J; Petranovic Ovčariček P; Vrachimis A; Zerdoud S; Putora PM
    Oncology; 2022; 100(2):74-81. PubMed ID: 34788758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
    van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
    Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
    [No Abstract]   [Full Text] [Related]  

  • 12. Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System.
    Trimboli P; Piccardo A; Signore A; Valabrega S; Barnabei A; Santolamazza G; Di Paolo A; Stati V; Chiefari A; Vottari S; Simmaco M; Ferrarazzo G; Ceriani L; Appetecchia M; Giovanella L
    Thyroid; 2020 May; 30(5):713-719. PubMed ID: 31973653
    [No Abstract]   [Full Text] [Related]  

  • 13. Radioiodine therapy in the different stages of differentiated thyroid cancer.
    Valerio L; Maino F; Castagna MG; Pacini F
    Best Pract Res Clin Endocrinol Metab; 2023 Jan; 37(1):101703. PubMed ID: 36151009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?
    Moreno I; Hirsch D; Duskin-Bitan H; Dicker-Cohen T; Shimon I; Robenshtok E
    Thyroid; 2020 Jun; 30(6):863-870. PubMed ID: 31928205
    [No Abstract]   [Full Text] [Related]  

  • 15. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
    Lind P; Igerc I; Kohlfürst S
    Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
    Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
    PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine Remnant Ablation for Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis.
    James DL; Ryan ÉJ; Davey MG; Quinn AJ; Heath DP; Garry SJ; Boland MR; Young O; Lowery AJ; Kerin MJ
    JAMA Otolaryngol Head Neck Surg; 2021 Jun; 147(6):544-552. PubMed ID: 33792650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
    Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
    Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis.
    Vardarli I; Weidemann F; Aboukoura M; Herrmann K; Binse I; Görges R
    BMC Cancer; 2020 Jun; 20(1):550. PubMed ID: 32539683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.